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1083-l 38 Additive Effects of Statin Combined With Angiotensin 
Converting Enzyme Inhibitor on Vasomotion in 
Hypercholesterolemic Patients 
Kwang K. Koh, Ji W. Son. Jeong Y. Ahn, Seuna H. Han, Eak K. Shin, Gachon Medical 
School, Incheon, South Korea 
Background: HMG-CoA reductase inhibitor. statins and ramipril prevented or retarded 
the progression of coronary heart disease in large-scaled, clinical studies. Endothelial 
function plays an important role in the pathogenesis of atherosclerosis. Because the 
mechanisms of the blological effects of statins and antiotensin converting enzyme inhibl- 
tar therapies differ, we studied the vascular responses to these therapies in hypercholes- 
terolemic patients. 
Methods We adminlstered simvastatin 20 mg and placebo or ramipril IO mg daily during 
2 months with washout 2 months to 32 hypercholesterolemic patients. This study was 
randomwed, double-bknd, placebo-controlled. crOSSOYer in design. 
*=P<O.O5;“=P<O.Ol;‘“=p<O.OOl vs. Baseline. Data= mean+SD. Results Simvastatin 
alone or combined with ramipril significantly changed lipoproteins, and improved the per- 
cent flow-mediated dilator response (FMD) to hyperemia from 4.93t1.96 lo 6.56k1.94 by 
46*48% and from 4.66+1.66 to 6.76il.95 by 59a66%, respectively (both P<O.OOl) and 
reduced plasma levels of nitrate from 66r44 to 75+32 uM by 0252% and from 83+39 to 
65229 uM by 13t30%, respectively (P=O.l63 and P=O.O12. respectively). and plasma 
levels of malondialdehyde (MDA), a marker of free radical from 1.33kO.52 to l.lOr0.53 
uM by 6257% and from 1.34*0.60 lo 1.01+0.41 uM by 13r47%, respectively (P=O.O45 
and PcO.001, respectively), compared with baseline measurements. However, simvasta- 
tin combined with ramipril changed to greater extent FMD and plasma levels of nitrate 
and MDA than slmvastatin alone. Conclusions: Compared with simvastatin alone, 
added ramlprll to simvastatln showed additive effects on flow-mediated dilation and the 
plasma levels of nitrate and MDA in hypercholesterolemic patients. 
1083-l 39 Atorvastatin Suppresses the Expression of CD40 
Ligand and P-Selectin on Platelets in Patients With 
Hypercholesterolemia 
Yeo-Shin Hwanq Wen-Chan Tsai, Ching-Cheng Lin, Ye-Hsu Lu, Ying-Fu Chen, Chi- 
Kong Ho, Kaohslung Medical College, Kaohsiung, Taiwan,ROC 
Background: Hypercholesterolemia (HC), a risk factor for cardiovascular disease, is 
associated with Inflammation and the prothrombotic state. Recently a CD40-CD40 ligand 
(CD40L) interaction and the activation of platelet was claimed to play a major role in the 
patheogenesis in atherosclerosis. The aim of the study was to characterize the in vitro 
expression of CD40L and p-selectin in patients with HC and to investigate whether atorv- 
astatin (ATOR). a potent lipid-lowenng agent, can Influence the levels of these molecules 
and TNF-a. 
Methods Twelve patients with polygemic HC (total cholesterol > 220 mg/dl, or LDL > 
130 mgldl) without other associated inflammatory disease and 14 normal controls were 
enrolled in this study. Blood samples were obtained before and after 8 weeks of ATOR 
(IO mg/day) therapy in patient group. After isolation. half of the platelets were stimulated 
by the addition of ADP (5~mollL). Flow cytometry was used to analyze the expression of 
CD40L and p-selectin. TNF-a was measured by ELISA. 
Results: The production of TNF-a is correlated with wth VLDL (p= 0.002, R* = 0.50) and 
LDUHDL ratio (p= 0.020, R2 = 0.39). In normal controls, the expression of CD4OL and p- 
selectln increased significantly after the stimulation of ADP. In patients, the expression of 
CD40L show no difference between with or without ADP stimulation before treatment 
(CD40L: 0.57 f 0.55 vs 0 51 r 0.19 mean fluorescence intensity [MFI] p= NS), but after 6 
weeks of ATOR therapy, the addition of ADP can significantly increase the expression of 
CD40L (0.25 * 0.17 vs 0.59 * 0.45 MFI, p= 0.026). In the same time, after 8 weeks of 
ATOR therapy, the expression of CD40L and p-selectin decreased significantly ( CD40L: 
0.57 * 0.55 vs 0.25 f 0.17. p = 0.034; p-selectin: 2.3 + 1.4 YS 1.06 f 0.67, p= 0.006). 
Conclusion: In this shorl term study, ATOR can down-regulate the expression of CD4OL 
and p-selectin on platelets in patients with HC. We also found that the level of TNF-a was 
correlated with VLDL and LDUHDL ratio. We supposed that in addition lo Its effect on 
decreasing the cholesterol level, ATOR can intervene the Interaction of CD40-CD40L 
and the expression of p-selectin whrch may alleviate the prothrombotic potency of plate- 
lets III patients with HC. 
1083-140 Ezetimibe Coadministered With Atorvastatin Compared 
to Atorvastatin Alone in the Attainment of Low-Density 
Lipoprotein Goals Among High-Risk Patients With 
Hypercholesterolemia 
Evan A Stein, Steen Stender, Pedro Mata, Damien Ponsonnet, Lorenzo Melani, Philip 
Sager, Leslie Lipka, Ramachandran Suresh, Enrico Veltri, Metabolic and Atherosclerosis 
Research Center. Cincinnati, OH, Schering-Plough Research Institute, Kenilworth, NJ 
Background: Thus study evaluated ezetimibe (EZE) coadministered with atorvastatin 
(ATOR) in patients with heterozvaous familial hvoercholesterolemia. coronaw heart dis- ~I I .  
ease, or multiple cardiovascular risk factors. Methods: After dietary stabilization, a 6- to 
IO-week washout. and ATOR run-I” oeriod fooen-label ATOR 10 moldav~. 621 oatients _ ,,. 
with baseline LDL-C ~130 mg/dL and TG 1350 mg!dL on ATOR IO mg were randomized 
to two treatment arms; EZE 10 mg or addttional double-blind ATOR (IO mg) adminlstered 
daily for 4 weeks. The ATOR dose was doubled if LDL-C was >I00 mgldL afier 4 and/or 
9 weeks of treatment (maximum 60 mglday with ATOR alone; 40 mg/day with coadmints- 
tration). The primary endpoint was the proportton of patients achieving target LDL-C 
<lo0 mg/dL at week 14. Results: Addltlon of EZE to ATOR IO mglday followed by 
response-based titration of ATOR significantly increased the proportion of patients 
reaching target LDL-C to 22% (67/305) versus titration of ATOR alone of 7% (23/316; 
p<O.Ol). EZE+ATOR 10 mg significantly reduced LDL-C versus ATOR 20 mg at week 4 
(22.6% versus 6.6%; p<O.Ol). In addition, despite only 60% of subjects in the 
EZE+ATOR group being on ATOR 40 mg (none on 60 mg) and 65% of ATOR group on 
60 mg. the final (week 14) LDL-C reduction from randomization was 31.2% versus 
l&9%, respectively. EZE+ATOR was well tolerated. with a safety profile similar to ATOR 
alone. Conclusion: Adding EZE to ongoing ATOR provides significantly greater LDL-C 
reduction than continued doubling of ATOR dose alone, and results in 3 times as many 
patients reaching target LDL-C. This offers a highly efficacious and well tolerated new 
treatment approach in hypercholeslerolemia. 
1083-141 Heterozygous Familial Hypercholesterolemia: 
Coadministration of Ezetimibe Plus Atorvasatin 
William Vermaak, Xavier Pinto, Damien Ponsonnet, Philip Sager, Leslie Lipka, 
Ramachandran Suresh, Enrico Veltri. the Ezetimibe Study Group, Unrversiiy of Pretoria, 
Pretoria, South Africa, Schering-Plough Research Institute, Kenilworth, NJ 
Background: Effective control of LDL-C in heterozygous familial hypercholesterolemia 
(HeFH) patients is difficult. This study evaluated the efficacy and safety of ezetimibe 
(EZE) coadministered with atorvastatin (ATV), in HeFH patients. 
Methods: After dietary stabilization, a 6. to IO-week washout, and a M-week ATV 10 
mg/d run-in , 362 patients with LDL-C 2130 mq/dL (mean LDL-C 197 mg/dL) and TG 
a50 mgldL were randomized to EZE IO mgld or additional double-blind AN 10 mg/d for 
4 weeks. The ATV dose was doubled if LDL-C was >I00 mg/dL after 4 and/or 9 weeks to 
a maximum of 80 mgld with ATV alone and 40 mgld with EZE + AN. Endpoints were the 
proportion of patients achieving LDL-C 2100 mgldL at Week 14 and change in the lipid 
profile at 4 weeks. 
Results: Coadminlstration of EZE with ATV IO mgld followed by response-based titra- 
tion of AN, significantly increased the proportion of patients reaching target LDL-C ver- 
sus AT!! monotherapy uptitration (17% YS 4%; p<O.Ol). EZE + ATV IO mg significantly 
reduced LDL-C versus ATV 20 mg at Week 4 (23.6% versus 7.4%; p<O.Ol). Total-C, TG, 
and non-HDL-C were also significantly reduced (Figure). EZE + ATV was well tolerated, 
with a safety profile similar to ATV alone. 
Conclusion: In HeFH patients, adding EZE to ATV provides significantly greater reduc- 
tion in LDL-C and other lipid parameters than doubling the ATV’dose alone, and results 
in four times as many patients achieving target LDL-C. EZE + ATV offers a highly effica- 
cious and well tolerated therapeutic approach in HeFH. 
1083-i 42 Ezetimibe Coadministered With Low Dose Statins in 
Primary Hypercholesterolemia: Lipid Profiles 
Comparable to High-Dose Statin Monotherapy 
Philiu Saaer, Lorenzo Melani, Leslie Lipka, Alexandre Lebeaut, Ramachandran Suresh, 
Steven Sun, Enrico Veltri, the Ezetimibe Study Group, Schering-Plough Research 
Institute, Kenilworth. NJ 
Backgrounct Ezetimibe (EZE), a novel cholesterol absorption inhibitor, significantly low- 
ers LDL-C and TG and raises HDL-C. The addition of EZE to low-dose statins may result 
in similar LDL-C reductions as achieved with high-dose statin monotherapy. 
Methods: Data were analyzed from 4 Phase III, randomized, double-bknd. Pbo-con- 
trolled studies in pts with primary hypercholesterolemia in which EZE IOmg + statin 
IOmg was compared with Pbo + higher doses of statin alone (simvastatin (S) 60mg, ator- 
vastatin (A) 6Omg. pravastatin (P) 40mg, or lovastatin (L) 40mg). After dietary stabiliza- 
tion @ NCEP Step I), a 2.12.wk screening/washout period and a 4.wk, Pbo lead-an 
period, pts with basekne LDL-C 2145 to <250 mgldl and TG 5350 mgldl were random- 
ized to EZE + statin or Pbo + statin daily for 12 weeks. 
Results EZE + statin IOma resulted in similar LDL-C reductions as those achieved with 
higher doses of statins alone (table) and comparable or greater effects on HDL-C and TG 
cornoared lo statin monotheraw. The effects of EZE on LDL-C were indeoendent of the 
I  
statin tested. EZE had an excellent safety profile and was well tolerated. 
Conclusiorr The addition of EZE IO mg to low doses of statIns (IOmg) provides similar 
effects on LDL-C, HDL-C, and TG, compared to high-dose statin monotherapy (SBOmg, 
AEOmg, P40mg, L40mg). The addition of EZE to statins provides an alternatwe to high- 
dose statins for therapy of hypercholesterolemla. 
Percent Change from Drug Free Baseline to Endpoint 
256A ABSTRACTS - Vascular Disease, Hypertension, and Prevention JACC March 19,2003 
Para Ei!E/ PBOI EZEI PBOI Ei!E/ PBOl EZEl PBOI 
met SlOmg S80mg AlOmg ABOmg PlOmg P40mg LlOmg L40mg 
er (“=67) (“~67) (“~65) (“~62) (“=71) (n=67) (“=66) (“=66) 
LDL- -45.5 -44.7 -53.4 -53.8 -33.6 -31.1 -34.2 -30.5 
C’ 
HDL 8.6 a.2 9.0”’ 2.8 6.4 6.1 7.9 4.8 
-C’ 
TG” -26.1 -22.6 -31 .l -30.6 -22.9 -19.2 -18.8 -15.3 
‘Mean % change “Median % change *“P<O.O5 vs high dose StatIn (A60) 
1083-143 Does Pretreatment With Statins Before Percutaneus 
Coronary Intervention Reduce Myonecrosis? 
Su Min Chanq, Naji Yazbek, John A. Farmer, Nasser Lakkis, Baylor College of Medicine, 
Houston, TX 
Background: Cardiac enzyme elevation peri PCI carnes a worse outcome. Objective 
Determine if pretreatment with statins prior to PCI reduces enzyme elevation periPCl and 
other cardiac events (CE). Methods: 119 consecutive pts ( 63 on statins prior to PCI , 56 
not )underwent PCI were followed for 6 months. We compared the peri PCI cardiac 
enzyme elevation above 3 times normal and 6 months CE rate (death, peri PCI myocar- 
dial infarctlon (Ml), non fatal MI, target vessels revasculanzation (TVR) and unstable 
angina requiring hospitalization) Of not pretreated pts ,72% were on statins at follow up 
as compared to 98 % of pretreated pts. Results: Pretreated Patlents had more history of 
Ml or revascularization (63% vs 43%, p=O.O15), hyperllpidemia (60% vs 48% p=O.OOl), 
hypertension (83% vs 49% p=O.OZ) .The rest of baseline characteristics were similar 
including use of glycoprotein Ilb/llla inhibitors (60% vs 68% p=NS) and type of lesions. 
Pretreatment with statins had less periprocedure enzyme elevation (2% vs IO % p= 0.04) 
and lower CE rate at 6 months (21% vs 41% p=O.O15). After adjusting for 15 baseline 
characteristics, use of StatIns prior to PCI was associated with a decrease in the risk of 
enzyme elevation and CE. (OR 0.2, Cl 0.06-0.63, p=O.O06). Age > 65 years and type b2/ 
C lesions predicted worse outcome. Conclusion: Statins therapy prior to PCI may 
reduce periprocedure cardiac enzyme elevation and subsequent cardiac events. These 
results need to be confirmed in prospective randomized trials. 
StatIns n=63 
PeriPCl enzyme elevation 
death 



























1083-144 Statins Potentiate the Anticoagulant Effects of Low 
Molecular Weight Heparin 
Sirisha Puppala, Katherine Zamecki, Jennifer Zimmer, Rohit R. Arora, Biren Bhatt, Jesse 
Houghton, Mir Chowdhury, Charles R. Spillert. New Jersey Medical School, Newark, NJ 
Background: Pravastatin sodium (PS) has been shown to have an anticoagulant effect in 
patrents. We have shown that PS has anticoagulant effects which are unrelated to a tis- 
sue factor pathway. Whether PS can potentlate the anticoagulant effects of low molecu- 
lar weight heparln (LMWH, Dalteparin) IS discussed. 
Methods: One milliliter of titrated whole blood (CWB) was incubated for 10 minutes at 37 
degrees with the following: 20 ~1 water (control); 16 Kg/ml PS; 0.25 U/ml LMWH; 16 pgl 
ml PS and 0.25 U/ml LMWH combined. The clotting time (set) was determined on a Son- 
oclot Coagulation Analyzer, a miniviscometer, which is sensitive to early fibrin polymer 
generation. 
Results: The clotting times are as follows: control 355 f 74; PS 462 * 75; 
LMWH 636 * 191 and PS + LMWH 610 * 119. All values were significantly different from 
each other (~‘0.05 or less). 
Conclusion: PS prolongs clotting time as does LMWH when compared to the control. In 
addition. the combination of PS and LMWH prolongs clotting time when compared to 
either alone. The enhanced anticoagulant effects of this combination of drugs may also 
cxcur when used clinically. A rapid clinical blood clotting assay capable of monitoring 
these apparently beneficial effects would be an asset. 
1083-145 Variability in the ASCAl Gene but Not HMG-CoA 
Reductase Predicts Low-Density Lipoprotein Lowering 
Effects of Statins 
Gualberto Ruano. Chad Messer, Bradley Dain, Richard Judson. Carol Reed, Antonio 
Gotto. Genaissance Pharmaceuticals, New Haven, CT, Weill Cornell Medical College, 
New York, NY 
Background: ABCAI (ATP-binding cassette, sub-family A_ABCl_, member 1) is 
involved in Tangier disease and is known to play a role in cholesterol homeostasis but 
not in statin treatment. HMGCR (HMGCoA reductase) is the target for statins. We inves- 
tigated whether variability in these genes may be wolved in statin response using the 
STRENGTH study, &htin fisponse &am&d by @?ne+c &plotype Markers, a phar- 
macogenetic study of statin efficacy). 
Methods 425 patients with hyperlipidemla were randomly assigned to 6 weeks of treat- 
ment with one of three statins: 8Omg/day simvastatin (N=l48), EOmgiday atowastatin 
(N=l39) or 40mg/day pravastatin (N=l38). We sequenced the ABCAl and HMGCA 
genes in 679 hyperlipidemlc patients plus 93 other individuals. We constructed haplotype 
markers from unphased genotypes (Drysdale, et al, PNAS, 97:19, 2000). Each marker 
was tested for an associarion with LDL reduction using ANCOVA models. Permutation 
tests were used to adjust for the multiple markers considered. 
Results: We discovered 179 SNPs Including 30 novel, non-synomymous SNPs in 
ABCA1. We found a significant association between an ABCAl haplotype marker and 
LDL reduction by statin treatment (P~O.0001) The association is also seen in the Individ- 
ual statin groups with p-values ranging from 0.04 to 0.003. The marker Includes 
GLU(1192) ASP plus 4 other SNPs. Patients with tl copy of the marker respond wth 
10% less LDL reduction than those without the marker. There were no differences in 
basellne lipids or HDL response between individuals based on this marker. 
For HMGCR, sequencing in our cohort revealed 51 SNPs. We detected no association 
between haplotype markers of HMGCR and statln response. 
Conclusion: Genes involved in cholesterol and lipid metabolic dwases should be can- 
dldates for pharmacogenetic analysis of drug response. Drug targets. although useful for 
drug screening, may not influence interindiwdual differences in drug response. 
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804 Genetic Determinants of Atherosclerosis 
Monday, March 31, 2003, 9:15 a.m.-10:30 a.m. 
McCormick Place, Room S103 
9:15 a.m. 
804-l LOX-l Polymorphism as a Susceptibility Genetic Marker 
for Atherosclerosis 
Ruaaiero Manaq Fabrizio Clementi, Gianmarco Contino, Giovanni B. Forleo. Paola 
Borgiani, Annalisa Botta, Annamaria Nardone, Gaetano Chiricolo, Massimo Marchei, 
Alessia Romeo, Sabina Guarino, Clarissa Cola, Maria Rosaria D’Apice, Masslmo 
Federici, lbrahim Fahdi, Renato Laura, Francesco Romeo, Giuseppe Novelli. Jawahar L. 
Mehta, University of Tor Vergata, Rome, Italy, University of Arkansas for Medical 
Sciences, Little Rock, AR 
Background and Objectives: Atherosclerosis is the principal process contributing to the 
pathogenesis of coronary artery disease (CAD), cerebral infarctlon. and penpheral vas- 
cular disease. A large number of risk factors such as hypertension. hypercholester- 
olemia, diabetes, obesity, smoking and shear stress leads to endothelial activation and/ 
or dysfunction, which elicit a series of cellular interactions that culminate in atherogene- 
sis. Several biochemical and functional studies suggest that a lectm-like receptor for oxi- 
dized low-density-lipoprotein (ox-DL), termed LOX-l. may be involved in atherogenesis. 
A recent linkage study performed in a mouse model, identified LOX-l as candidate sus- 
ceptibility gene for human atherosclerosis. Aim of this study is to investigate the role of 
the LOX-1 gene in human atherosclerosis susceptibility through association studies in 
different populations. 
Mated&and Methods: We screened a group of 164 Italian individuals with angiographlc 
CAD phenotype (CAD; n=66) or without any angiographically demonstrable disease 
(CAD-free; w76) and a group of 35 individuals from Arkansas (CAD, n=14; CAD-free, 
n=21). 
Results: We charaderized five dtfferent SNPs (SNP l-5) at the LOX-l locus I” these 
populations. We demonstrated that SNP4 (A to G transltion) correlates with CAD with a 
high degree of specificity in the Italian population (X’ = 7,37: P. 0.007; ldf) and repro- 
duced this association also in the American group (X*=5.1 I; P. 0.0237; ldf). 
Conclus;on:On the basis of these data on the prevalence of LOX-l SNPs in two different 
angiographically documented CAD populations, we think that LOX-l may be a potent 
candidate gene for atherogenesls and endothelial dysfunction in response to ox-LDL. 
Work supported by the Italian Ministry of Universrty and Research (MIUR) 
9:30 a.m. 
804-2 Genetic Determinants of Nicotine-Induced 
Angiogenesis 
Edwin Chanq, Yan Wang, Hanh M. Bui. Johannes Jacobi, Christopher Heeschen, James 
J. Jang, John P. Cooke, Stanford University Medical School, Stanford, CA 
Background: Nicotine is a potent angiogenic agent which Induces tumor angiogenesis 
and plaque neovascularizatlon. The angiogenic effect of nicotine occurs at concentra- 
tions similar to those found in plasma of moderate smokers. Nlcotlne action is medlated 
by endothelial nicotlnic cholinergic receptors (nAChR). We hypothesize that stimulation 
of the nAChR activates signal transduction pathways and transcriptional pathways that 
an? distinct from other anglogenic factors. Methods: We identified nicotine-regulated 
genes by using subtraction hybndization technology to isolate the differentrally expressed 
genes. We also employed high-throughput microarray transcriptional profiling to examine 
and validate gene expression profiles. Human micro vascular endothelial cells were 
treated with vehicle or nicotine (IO-‘M), and were subjected to PCR-selected subtraction 
hybridization. Results: Nicotine increased proliferative but decreased apoptotlc indices in 
sub confluent proliferatmg endothelial cells (HUVEC and HCAECs) with respect to 
untreated cells. Hexamethonium blocked the anti-apoptotic effect of nicotine. In nicotine 
